Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Raw Materials (2016 - 2025)

Avanos Medical's Raw Materials history spans 11 years, with the latest figure at $3.4 million for Q3 2024.

  • For Q3 2024, Raw Materials fell 24.44% year-over-year to $3.4 million; the TTM value through Sep 2024 reached $3.4 million, down 24.44%, while the annual FY2023 figure was $4.6 million, 130.0% up from the prior year.
  • Raw Materials for Q3 2024 was $3.4 million at Avanos Medical, down from $3.9 million in the prior quarter.
  • Across five years, Raw Materials topped out at $60.1 million in Q2 2020 and bottomed at $2.0 million in Q4 2022.
  • The 5-year median for Raw Materials is $45.0 million (2022), against an average of $29.0 million.
  • The largest annual shift saw Raw Materials surged 700.0% in 2021 before it plummeted 95.81% in 2022.
  • A 5-year view of Raw Materials shows it stood at $6.7 million in 2020, then surged by 611.94% to $47.7 million in 2021, then tumbled by 95.81% to $2.0 million in 2022, then soared by 130.0% to $4.6 million in 2023, then fell by 26.09% to $3.4 million in 2024.
  • Per Business Quant, the three most recent readings for AVNS's Raw Materials are $3.4 million (Q3 2024), $3.9 million (Q2 2024), and $51.0 million (Q1 2024).